Kite Presents New Data on Patient Outcomes with CAR T-Cell Therapy at the 7th European CAR T-Cell Meeting, 6-8 February, Strasbourg, France
February 6, 2025 – Clinical Trials, Drug Discovery, Other, Pharmaceutical – CAR T-cell, European CAR T-cell Meeting, Gilead Sciences, Kite Pharma
6 February 2025 — Stockley Park, UK — Kite, a Gilead Company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France. Data from Italy demonstrate Kite’s commitment to changing patient outcomes for people living with difficult-to-treat blood cancers through manufacturing excellence and support programmes.
“As the leader in CAR-T cell therapy, Kite is pleased to add to the important scientific exchange during the 7th European CAR T-Cell Meeting, with a focus on improving outcomes for people living with difficult-to-treat blood cancers,” said Dan Tovar, Interim Head of Medical Affairs, Kite, Australia, Canada and Europe (ACE) Region . “These presentations reinforce the importance of support programmes and infrastructure needed to meet the ongoing unmet need for patients and improve healthcare system resources.”
| Abstract Title |
| CARE-TOGETHER: The First Italian Patient Support Program for CAR T Patients S. Bramanti; A. Chiappella; A. Di Rocco; F. Sorà; E. Ateri; R. L. Balzano; S. Cupri; I. Martelli; F. Torelli; F. Ceccherini |
| Optimizing Care After CAR T-cell Therapy: Reduction of In-hospital Monitoring Duration Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Infusion T. Best; A. Lee; Y. Zheng; J.J. Kim |
| Manufacturing Commercial Axicabtagene Ciloleucel (Axi-Cel) in Italy for Patients with Relapsed/Refractory NHL: A 2-Year Retrospective Analysis B. Casadei; M. Ganzetti; F. Torelli; R. Balzano; D. Myers |
| Increasing CAR T delivery capacity in Certified Healthcare Facilities: An impact assessment of shifting resources from ASCT to CAR T in second-line treatment of diffuse large B-cell lymphoma M. Shafey; A. Davies; I. Baltadakis; A. Barber; E. Church; A. Laws; B. Doble |
About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing. Visit: www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017. Visit: www.gilead.com.
